{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:55Z","timestamp":1780031155292,"version":"3.53.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Granzyme A (GzmA) has been identified as a key amplifier of sepsis-related inflammation in experimental models without contributing to pathogen clearance. However, its behavior and clinical relevance in human bacterial sepsis remain unknown. We aimed to characterize circulating GzmA in secondary peritonitis and explore its associations with clinical severity and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center prospective cohort study of 42 adults with secondary peritonitis at Lozano Blesa Clinical Hospital (Zaragoza, Spain), with 31 healthy controls. Peripheral blood was obtained at baseline, 24\u00a0h, and 48\u00a0h. Serum GzmA concentration and activity, GzmB, cytokines, and endothelial and coagulation markers were measured. Analyses included comparisons across Sepsis-3 severity strata and exploratory prognostic models (logistic regression and receiver operating characteristic curves) evaluating associations between baseline biomarkers and mortality. Sensitivity analyses were performed after excluding patients meeting predefined immunosuppression criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, GzmA concentrations (2.3-fold, q-value = 5.41\u00d710\n                      <jats:sup>\u221212<\/jats:sup>\n                      ) and GzmA enzymatic activity (q-value = 6.75 \u00d7 10\n                      <jats:sup>-<\/jats:sup>\n                      \u00b3) were significantly higher in patients than controls, whereas GzmB did not differ (q-value = 0.332). Across baseline severity categories, VCAM-1 showed the clearest gradient (q-value = 0.017), while GzmA concentrations were numerically highest in septic shock (median 165.4 pg\/mL). GzmA remained elevated through 48\u00a0h, and non-survivors had higher baseline levels than survivors. Each doubling of baseline GzmA was associated with higher overall in-hospital mortality (OR 2.52; 95% CI 1.11-5.75, p=0.028), with associations persisting after adjustment for age and comorbidity. Sensitivity analyses excluding immunosuppressed patients yielded a clearer association between GzmA and baseline severity, and confirmed its association with mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Circulating GzmA, but not GzmB, is markedly upregulated, remains elevated during early follow-up, and is preliminarily associated with mortality-related outcomes. These exploratory findings are consistent with experimental models and support further evaluations of extracellular GzmA to investigate its biological and potential translational relevance in sepsis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1763092","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:53:39Z","timestamp":1780030419000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating granzyme A is elevated within the dysregulated host response and associates with mortality in abdominal sepsis"],"prefix":"10.3389","volume":"17","author":[{"given":"Galadriel","family":"Pellejero-Sagastizabal","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Hospital Cl\u00ednico Universitario Lozano Blesa","place":["Zaragoza, Spain"]},{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Department of Medicine, Psychiatry and Dermatology, University of Zaragoza","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Esteban","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Letona-Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Hospital Cl\u00ednico Universitario Lozano Blesa","place":["Zaragoza, Spain"]},{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Andr\u00e9s-Tovar","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Sierra","sequence":"additional","affiliation":[{"name":"Servicio Urgencias, Hospital Cli\u0301nico Universitario Lozano Blesa","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Senan-Salinas","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Instituto de Carboqui\u0301mica ICB-CSIC.","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Ga\u0301lvez","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]},{"name":"Instituto de Carboqui\u0301mica ICB-CSIC.","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia\u0301n","family":"Pardo","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]},{"name":"Department of Microbiology, Pediatrics, Radiology, Preventive Medicine and Public Health, University of Zaragoza","place":["Zaragoza, Spain"]},{"name":"Red Espa\u00f1ola de Terapias Avanzadas (TERAV), and Consorcio Estatal en Red para el Desarrollo de Medicamentos de Terapias Avanzadas (Certera), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Morte-Romea","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Hospital Cl\u00ednico Universitario Lozano Blesa","place":["Zaragoza, Spain"]},{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maykel","family":"Arias","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]},{"name":"Department of Microbiology, Pediatrics, Radiology, Preventive Medicine and Public Health, University of Zaragoza","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ramo\u0301n","family":"Pan\u0303o-Pardo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Hospital Cl\u00ednico Universitario Lozano Blesa","place":["Zaragoza, Spain"]},{"name":"Biomedical Research Centre of Arago\u0301n (CIBA), Instituto de Investigacio\u0301n Sanitaria Arago\u0301n (IIS Arago\u0301n)","place":["Zaragoza, Spain"]},{"name":"Department of Medicine, Psychiatry and Dermatology, University of Zaragoza","place":["Zaragoza, Spain"]},{"name":"Centro de Investigacio\u0301n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019-results from a systematic review and meta-analysis","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.50","article-title":"Sepsis, severe sepsis and septic shock: Changes in incidence, pathogens and outcomes","volume":"10","author":"Martin","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medin.2022.03.017","article-title":"Pathophysiology of septic shock","volume":"46","author":"Chiscano-Cam\u00f3n","year":"2022","journal-title":"Med Intens"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: Results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2006.09.006","article-title":"Management of peritonitis in the critically ill patient","volume":"86","author":"Ordo\u00f1ez","year":"2006","journal-title":"Surg Clinics North America"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199706000-00012","article-title":"Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection","volume":"225","author":"Wickel","year":"1997","journal-title":"Ann Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s0039-6060(96)80195-4","article-title":"Hypothesis: cytokines in Compartmentalization of intraabdominal infection","volume":"119","author":"Schein","year":"1996"},{"key":"B10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/sur.2012.028","article-title":"The efficacy of procalcitonin as a biomarker in the management of sepsis: Slaying dragons or tilting at windmills","volume":"14","author":"Sridharan","year":"2013","journal-title":"Surg Infect (Larchmt)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/S13054-024-04964-6","article-title":"Towards personalized medicine: a scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"107476","DOI":"10.1016\/j.pharmthera.2020.107476","article-title":"Immunotherapy in sepsis - brake or accelerate","volume":"208","author":"Steinhagen","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181e7c5c9","article-title":"A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis","volume":"38","author":"Rice","year":"2010","journal-title":"Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1086\/339549","article-title":"Clinical trials of immunomodulatory therapies in severe sepsis and septic shock","volume":"34","author":"Vincent","year":"2002","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2009.02.004","article-title":"The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation","volume":"11","author":"Pardo","year":"2009","journal-title":"Microbes Infect"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.06.012","article-title":"Elucidating sources and roles of granzymes A and B during bacterial infection and sepsis","volume":"8","author":"Arias","year":"2014","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4137563","DOI":"10.1155\/2017\/4137563","article-title":"Expression and function of granzymes A and B in escherichia coli peritonitis and sepsis","volume":"2017","author":"Garc\u00eda-Laorden","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.49288","article-title":"Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis","volume":"11","author":"Garz\u00f3n-Titua\u00f1a","year":"2021","journal-title":"Theranostics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMMUNI.2008.08.014","article-title":"Human and mouse granzyme A induce a proinflammatory cytokine response","volume":"29","author":"Metkar","year":"2008","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.59418","article-title":"Biological relevance of Granzymes A and K during E. coli sepsis","volume":"11","author":"Uranga-Murillo","year":"2021","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRECAN.2017.04.001","article-title":"The untold story of granzymes in oncoimmunology: novel opportunities with old acquaintances","volume":"3","author":"Arias","year":"2017","journal-title":"Trends Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01054","article-title":"The multifaceted function of granzymes in sepsis: some facts and a lot to discover","volume":"11","author":"Garz\u00f3n-Titua\u00f1a","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-023-01660-5","article-title":"The pathophysiology of sepsis and precision-medicine-based immunotherapy","volume":"25","author":"Giamarellos-Bourboulis","year":"2024","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"k1407","DOI":"10.1136\/bmj.k1407","article-title":"Secondary peritonitis: Principles of diagnosis and intervention","volume":"361","author":"Ross","year":"2018","journal-title":"BMJ (Onl)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15301","article-title":"Causes of acute peritonitis and its complication","volume":"13","author":"Kumar","year":"2021","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jama.2016.20328","article-title":"Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit","volume":"317","author":"Raith","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"502172","DOI":"10.1016\/J.MEDINE.2025.502172","article-title":"Mortality time frame variability in septic shock clinical trials: A systematic review","volume":"50","author":"Laserna","year":"2025","journal-title":"Med Intens (Eng Ed)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/J.2517-6161.1995.TB02031.X","article-title":"Controlling the false discovery rate: A practical and\u00a0powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-89010-0_5","article-title":"Linear mixed models","author":"L\u00f3pez","year":"2022","journal-title":"Multivar Stat Mach\u00a0Learn Methods For Genomic Predict"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1378\/CHEST.125.4.1458","article-title":"Prediction of risk of death using 30-day outcome: A practical end point for quality auditing in intensive care","volume":"125","author":"Graham","year":"2004","journal-title":"Chest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.12873","article-title":"In-Hospital vs 30-Day Sepsis Mortality at US Safety-Net and Non\u2013Safety-Net Hospitals","volume":"7","author":"Law","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0167-5877(00)00115-X","article-title":"Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests","volume":"45","author":"Greiner","year":"2000","journal-title":"Prev Vet Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic test","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/08830180903247889","article-title":"Expression of multiple granzymes by cytotoxic t lymphocyte implies that they activate diverse apoptotic pathways in target cells","volume":"29","author":"Zhou","year":"2010","journal-title":"Int Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/J.1399-0039.2008.01013.X","article-title":"Non-apoptotic functions of granzymes","volume":"71","author":"Romero","year":"2008","journal-title":"Tissue Antigens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00931","article-title":"Modulation of inflammation by extracellular granzyme A","volume":"11","author":"van Daalen","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000443401","article-title":"Granzymes A and B Regulate the Local Inflammatory Response during Klebsiella pneumoniae Pneumonia","volume":"8","author":"Garc\u00eda-Laorden","year":"2016","journal-title":"J Innate Immun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2016.84","article-title":"Granzymes A and K differentially potentiate LPS-induced cytokine response","volume":"2","author":"Wensink","year":"2016","journal-title":"Cell Death Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-058-8_23","article-title":"Murine model of polymicrobial septic peritonitis using Cecal Ligation and Puncture (CLP)","volume":"602","author":"Medina","year":"2010","journal-title":"Methods Mol Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005823","article-title":"Expression of intra- and extracellular granzymes in patients with typhoid fever","volume":"11","author":"de Jong","year":"2017","journal-title":"PloS NeglTrop Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00116.2016","article-title":"Granzyme A impairs host defense during Streptococcus pneumoniae pneumonia","volume":"311","author":"van den Boogaard","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/S00134-005-2720-3","article-title":"Elastase and granzymes during meningococcal disease in children: correlation to disease severity","volume":"31","author":"Van Woensel","year":"2005","journal-title":"Intensive Care Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e31823fca44","article-title":"Increased granzyme levels in cytotoxic T lymphocytes are associated with disease severity in emergency department patients with severe sepsis","volume":"37","author":"Napoli","year":"2012","journal-title":"Shock"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1086\/315642","article-title":"Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria","volume":"182","author":"Lauw","year":"2000","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13017-024-00552-9","article-title":"Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J Emergency Surg"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13017-024-00551-W","article-title":"Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J Emergency Surg"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4269\/AJTMH.20-1369","article-title":"Elevated extracellular levels of granzymes in patients with scrub typhus","volume":"105","author":"Hwang","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.56","article-title":"A novel proinflammatory role for granzyme A","volume":"8","author":"Van Eck","year":"2017","journal-title":"Cell Death Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2477911","article-title":"Combination of exhaled volatile organic compounds with serum biomarkers predicts respiratory infection severity","volume":"31","author":"Esteban","year":"2025","journal-title":"Pulmonology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp Mol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/S40560-015-0075-6","article-title":"Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC","volume":"3","author":"Madoiwa","year":"2015","journal-title":"J Intensive Care"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13699","article-title":"Extracellular granzyme K mediates endothelial activation through the cleavage of protease-activated receptor-1","volume":"283","author":"Sharma","year":"2016","journal-title":"FEBS J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030407","article-title":"IL-6 baseline values and dynamic changes in predicting sepsis mortality: a systematic review and meta-analysis","volume":"15","author":"Varga","year":"2025","journal-title":"Biomolecules"},{"key":"B55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.200801-131OC","article-title":"Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock","volume":"178","author":"Wong","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/S13054-023-04525-3","article-title":"Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis","volume":"27","author":"Rosenberger","year":"2023","journal-title":"Crit Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.05.55","article-title":"New clinical criteria for septic shock: serum lactate level as new emerging vital sign","volume":"8","author":"Lee","year":"2016","journal-title":"J Thorac Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2112","article-title":"Procalcitonin monitoring as a guide for\u00a0antimicrobial therapy: a review of current literature","volume":"38","author":"Covington","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3844\/ajidsp.2007.17.23","article-title":"Circulating granzymes are associated with bloodstream infection and death in febrile medical patients","volume":"3","author":"Groeneveld","year":"2007","journal-title":"Am J Infect Dis"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1016\/j.mucimm.2024.08.006","article-title":"Distinct cell death pathways induced by granzymes collectively protect against intestinal Salmonella infection","volume-title":"Mucosal Immunol.","author":"Chawla","year":"2024"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115694","article-title":"High mortality rate of septic patients with high blood granzyme B concentrations","volume":"103","author":"Lorente","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051461","article-title":"Association between plasma granzyme B levels, organ failure, and 28-day mortality prediction in patients with sepsis","volume":"14","author":"Ki","year":"2025","journal-title":"J Clin Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.coi.2019.04.013","article-title":"Granulysin: killer lymphocyte safeguard against microbes","volume":"60","author":"Dotiwala","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.062","article-title":"Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes","volume":"157","author":"Walch","year":"2014","journal-title":"Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.169","article-title":"Control of granzymes by serpins","volume":"17","author":"Kaiserman","year":"2010","journal-title":"Cell Death Diff"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.525808","article-title":"Identification of serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A","volume":"289","author":"Kaiserman","year":"2014","journal-title":"J Biol Chem"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(88)90043-0","article-title":"Inhibition of lymphocyte protease granzyme A by antithrombin III","volume":"25","author":"Masson","year":"1988","journal-title":"Mol Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(99)00282-4","article-title":"Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors","volume":"1477","author":"Kam","year":"2000","journal-title":"Biochim Biophys Acta Protein Struct Mol Enzymol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s001340051122","article-title":"Clinical trials of mediator-directed therapy in sepsis: what have we learned","volume":"26","author":"Marshall","year":"2000","journal-title":"Intensive Care Med Supplem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000145229.59014.6c","article-title":"Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab\u2019)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels","volume":"32","author":"Panacek","year":"2004","journal-title":"Crit Care Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group","volume":"25","author":"Opal","year":"1997","journal-title":"Crit Care Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01926","article-title":"Precision immunotherapy for sepsis","volume":"9","author":"van Ton","year":"2018","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkaf001","article-title":"Recent advances of precision immunotherapy in sepsis","volume":"13","author":"Arapis","year":"2025","journal-title":"Burns Trauma"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:53:49Z","timestamp":1780030429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2026.1763092"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1763092","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1763092"}}